Baric Transcribed Interview (Redacted) — page 117

DC.Scheduling@LexitasLegal.com always be like a material transfer agreement? DR. BARIC: Oh, absolutely. Well -- MS. SALAZAR: That may or may not -- DR. BARIC: Yes. MS. SALAZAR: -- are there cases where there may not be? DR. BARIC: Well, sometimes for large program project grants there would be a universal MTA created among all of the researchers so that you can share reagents. That's one form. And the other form is somebody will call and ask you for reagents and you do an MTA agreement. MS. SALAZAR: Going back to -- DR. BARIC: I would say that 99 percent of them were done as MTA agreements. There would probably be outliers, occasionally, but that would be on existing projects where collaborations exist through a grant, and reagents are needed to further the aims of the grant. MS. SALAZAR: Did you have a UBMTA with NIH-RML? What's the date on this? It's from 2023, on pangolin beta coronaviruses, where it looks like you would be providing original material to Vincent Munster from RML. Pangolin coronavirus was the original material, and the transmittal fee to reimburse the provider for preparation and distribution costs amount is zero. Is that something that was executed?